Latest:

Biotech Bulls: three skyrocketing stocks after earnings week
Eli Lilly’s antibody treatment for Alzheimer’s disease has shown to slow disease progression by 35% in Phase 3 trials! The 20 years of research that led to this breakthrough have provided key insights into tracking the progress and mechanisms of Alzheimer’s disease progression.